09 June 2016
R&D team are a UK first
approach AWP clinical trials week, the Research and Development
Team have received the first UK consent for a global clinical trial
run by Janssen.
The 'Sustain 2' trial aims to assess the effectiveness and
safety of the use of a nasal spray for treatment of
treatment-resistant depression (TRD).
Esketamine spray is thought to decrease TRD by stimulating
the brain to produce more proteins in an area responsible for
complex cognitive, emotional, and behavioural functioning. Initial findings with Esketamine treatment suggest
that it may be a useful treatment for depression.
Clinical studies officer and project lead Heather Tinkler said,
"It has been a bit of a challenge to get this study up and running,
especially as we were the first UK site to open. It feels great to
now be able to recruit service users and as a result of the
enthusiasm and hard work of the clinical teams involved, we have
been able to consent and screen the first UK participant!
"Although we don't know how effective the esketamine treatment
will be, this is an exciting opportunity for our service users to
explore new treatment options that aren't yet available and to help
with understanding treatment-resistant depression."
Congratulations to our research team for their great work in
making sure latest research opportunities are offered to our
service users and carers.